Coxiella vaccine aimed at reducing public health risk by preventing shedding of the agent is, as our regulatory partners are well aware, very high priority. Coxiellosis poses a threat to goat industry sustainability as proximity to human populations by both direct contact and prevailing winds pose potential threat to human populations nearby. Increasing urban ownership of companion goats pose additional potential human health risk and increased awareness of the potential risk to at-risk humans of production livestock nearby.

But Coxiella vaccine is an issue of its own, with unique challenges... Relative to AGF’s more general thinking about supporting vaccine work:

I am hopeful that your meeting will serve as a means for a frank discuss on what is involved in vaccine development, what regulatory steps, how to approach and meets the needs of biologics industry partners, how to set realistic time lines, outcomes and budgets - and is AGF interested in supporting pilot projects, or projects that are further along in the development process? Is it more realistic to secure importation of an existing world-wide vaccine, or commit long-term to development of a domestic vaccine?

I would be happy to provide input at another time and regret that I won’t be able to join in

Joannie